Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 1/2 3Phase 2 2Phase 3 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 251Lymphoma 241Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Leukemia 178Lymphoma, Large B-Cell, Diffuse 167Multiple Myeloma 166Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 146Leukemia, Myeloid, Acute 136Myelodysplastic Syndromes 116Hodgkin Disease 115Lymphoma, Follicular 113Burkitt Lymphoma 108Lymphoma, Mantle-Cell 104Lymphoma, B-Cell, Marginal Zone 76Lymphoma, Large-Cell, Immunoblastic 64Neoplasms, Plasma Cell 59Recurrence 58Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Myeloproliferative Disorders 53Neoplasms 49Leukemia, Myeloid, Chronic-Phase 49Triple Negative Breast Neoplasms 47Leukemia, Myeloid, Accelerated Phase 47Melanoma 46Leukemia, Myelomonocytic, Chronic 46Dendritic Cell Sarcoma, Interdigitating 46Waldenstrom Macroglobulinemia 42Hematologic Neoplasms 41Congenital Abnormalities 39

Interventions

Doxorubicin 4Gemcitabine 3pembrolizumab 2pazopanib 2fludarabine 2cixutumumab 2brostallicin 2Sorafenib 2Radiation Dose Hypofractionation 2Docetaxel 2Cyclophosphamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1tazemetostat 1sotigalimab 1soblidotin 1romidepsin 1reolysin 1perifosine 1pasireotide 1lorvotuzumab mertansine 1ixabepilone 1interferon gamma-1b 1exatecan 1durvalumab 1drozitumab 1atezolizumab 1Trastuzumab 1Trabectedin 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Synovial × Cyclophosphamide × Clear all
NCT03967223 2026-04-17

IGNYTE-ESO

USWM, LLC (dba US WorldMeds)

Phase 2 Active not recruiting
103 enrolled
Sarcoma

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

GlaxoSmithKline

Phase 2 Withdrawn
Sarcoma

Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡